$ONCO News

Oncopeptides Announces First Patient Enrollment In Clinical "Window-Of-Opportunity" Study Evaluating Proprietary Peptide Drug Conjugate Platform In Glioblastoma

UPDATED: Onconetix Announces 1-For-10 Reverse Stock Split, Effective May 21, 2026

Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?

Onconetix Q1 EPS $(6.71) Up From $(225.25) YoY, Sales $21.457K Down From $101.630K YoY

Onconetix Andrew Oakley Resigns As Chairman Of Board; Co. Appoints Sammy Dorf As Chairman Of The Board Effective April 23, 2026

Onconetix Stock Skyrockets After Realbotix Ships Vinci-Equipped Robot To Ericsson

Onconetix shares are trading higher after the company announced Realbotix, its pending acquisition target, has delivered its first Vinci-equipped humanoid robot to Ericsson.

Onconetix shares are trading higher after the company announced Realbotix, its pending acquisition target, has delivered its first Vinci-equipped humanoid robot to Ericsson.

Onconetix Appoints David White CEO, Effective March 18, Succeeding Interim CEO Karina Fedasz

Onconetix Shares Halted On Circuit Breaker At $3.53/Share

What's Going On With Onconetix Shares On Friday?

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Onconetix Announces 1-For-5 Reverse Stock Split, Effective March 25

Onconetix, Inc. (ONCO) M&A Call Transcript

Is Onconetix Inc Gaining or Losing Market Support?

Realbotix Announces the Sale of Realbotix, LLC Subsidiary to Onconetix

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times